For more than a decade, tens of thousands of people have claimed that Johnson & Johnson's baby powder gave them ovarian cancer – and the company has now offered billions to settle. In July 2026, the New Jersey-based healthcare giant said it would pay up to $5.5bn (£4.14bn) to resolve about 76,000 lawsuits in the US alleging that its talc-based products caused ovarian cancer. The landmark deal, if approved, would end one of the longest-running consumer safety battles in modern history.
The basics are straightforward: Johnson & Johnson (J&J) has offered to settle most of the remaining talc-related claims. The settlement covers cases consolidated in a federal court in New Jersey and related state court cases – representing nearly all outstanding ovarian cancer lawsuits. J&J denies that its talc caused cancer, calling the allegations “meritless,” but has changed its baby powder formula and stopped selling talc-based powder globally in 2022 (it ended US sales in 2020). The company’s vice president of litigation, Erik Haas, said J&J was confident it would have “ultimately prevailed” in court but wanted to “put this matter behind it.”
“J&J offers $5.5bn to settle 76,000 talc cancer lawsuits; explains the science, UK links and what happens next.”
To understand why this matters, you need to know about talc. Talc is a natural mineral made of magnesium, silicon, oxygen and hydrogen. It is prized for its ability to absorb moisture and reduce friction – hence its use in baby powder. But talc is mined from seams that often lie close to asbestos, a material known to cause cancer. Lawsuits against J&J, which began as early as 2009, have alleged that the company’s talc products were contaminated with asbestos, leading to ovarian cancer. J&J has consistently denied this, pointing to studies it says show talc is safe and does not contain asbestos. The company also won a significant court victory in July 2026, when a federal court questioned plaintiffs’ ability to prove that talc directly caused their cancer.
Why should UK readers care? The UK is not directly part of these US lawsuits, but the implications are global. J&J’s former consumer health business, Kenvue, holds liability for Johnson’s baby powder outside North America. Kenvue owns well-known brands including Band-Aid, Listerine, and Calpol – a common children’s painkiller sold in UK pharmacies. While the product in UK shops today is cornstarch-based, the legal battle has already shaken consumer trust in household names. The settlement also highlights wider concerns about product safety and corporate accountability that resonate with UK shoppers.
Q: What is talc and why is it linked to cancer? Talc is a mineral used in cosmetics and powder products. It can be contaminated with asbestos, a known carcinogen, because they are often found together in nature. Lawsuits claim that J&J’s talc products caused ovarian cancer due to asbestos contamination. J&J disputes this, stating that studies show its talc is safe and asbestos-free.
Q: How much is J&J paying and who is covered? J&J has offered up to $5.5bn to settle about 76,000 ovarian cancer claims. The company will pay $3bn in 2027 and further payments in 2028, with potential additional costs depending on participation. The deal must be accepted by 95% of the ovarian cancer claimants to become final.
Q: Does this affect UK consumers? Directly, no – the settlement is US-specific. However, Kenvue, the company responsible for Johnson’s baby powder outside North America, could face separate liabilities. UK consumers should note that the product sold in Britain has been cornstarch-based since 2022, so the original talc formula is no longer on shelves.
What happens next? The settlement still needs approval from at least 95% of the ovarian cancer claimants in state and federal courts. If accepted, it would bring closure to a legal saga that has lasted nearly two decades. Meanwhile, J&J has said it will continue to defend itself in any remaining cases, but this deal – if finalised – would mark the end of the biggest chapter of the baby powder litigation.